ICAAC 2012: Progression of Anal Neoplasia is Common among Gay Men with HIV
- Details
- Category: Cancer/Malignancies
- Published on Thursday, 13 September 2012 00:00
- Written by Liz Highleyman
Nearly 40% of HIV positive men with low-grade anal neoplasia may progress to high-grade neoplasia or anal cancer, according to a Spanish study presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) this week in San Francisco. Younger age and shorter duration of HIV infection were risk factors for worsening disease.
ICAAC 2012: HCV Polymerase Inhibitor Sofosbuvir Appears Safe and Effective for HIV/HCV Coinfected People
- Details
- Category: HCV Treatment
- Published on Wednesday, 12 September 2012 00:00
- Written by Liz Highleyman
HIV/
HCV coinfected people taking the experimental hepatitis C virus (HCV) polymerase inhibitor sofosbuvir (formerly GS-7977) experienced a rapid decline in HCV viral load similar to that seen in HIV negative patients, researchers reported this week at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco. Side effects were also similar, and there was no sign of interactions with antiretroviral drugs in this 14-day study
ICAAC 2012: Stribild Quad Pill Has Potent Anti-HIV Activity with Fewer Side Effects
- Details
- Category: HIV Treatment
- Published on Tuesday, 11 September 2012 00:00
- Written by Liz Highleyman
An integrated analysis of data from Phase 2 and 3 trials, presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this week in San Francisco, showed that the newly approved Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) single-tablet regimen had antiviral efficacy at least as good as comparison regimens, and was associated with fewer adverse events than Atripla or boosted atazanavir (Reyataz).
ICAAC 2012: New Long-acting HIV Fusion Inhibitor Albuvirtide Looks Promising in Early Studies
- Details
- Category: HIV Treatment
- Published on Tuesday, 11 September 2012 00:00
- Written by Liz Highleyman
A new fusion inhibitor that prevents HIV entry into cells showed potent antiviral activity in early clinical studies and has a long half-life suggesting it may be suitable for once-weekly dosing, Chinese researchers reported yesterday at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco. 
ICAAC 2012: Hepatitis B Vaccine Effective Long-term, but Some Lose Protection after 15 Years
- Details
- Category: HBV Vaccines
- Published on Tuesday, 11 September 2012 00:00
- Written by Liz Highleyman
Nearly all children who received 3 doses of the Engerix-B hepatitis B vaccine achieved protective immunity, but about 20% fell below the protective antibody threshold by year 15 and could benefit from a booster shot, Canadian researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this week in San Francisco. 
More Articles...
- ICAAC 2012: Experimental Nitroimidazole TBA-354 Shows Promise against Tuberculosis in Early Studies
- Coverage of the 2012 Interscience Conference on Antimicrobial Agents and Chemotherapy
- ICAAC 2012: HIV+ People Have Heart Attacks Younger, Receive Later Care, Die More Often
- ICAAC Meeting Underway in San Francisco -- HIV, HCV, HPV, Flu, and More
Web Design and Development by